|
STON2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62581059726108E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.94049245958195E-14 |
| Normal-vs-Stage2 |
9.50759999951423E-07 |
| Normal-vs-Stage3 |
3.90265597616235E-12 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
7.222200E-01 |
| Stage1-vs-Stage3 |
7.709200E-01 |
| Stage1-vs-Stage4 |
1.214360E-04 |
| Stage2-vs-Stage3 |
6.152200E-01 |
| Stage2-vs-Stage4 |
1.613830E-02 |
| Stage3-vs-Stage4 |
3.162300E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.54654067330284E-13 |
| Normal-vs-AfricanAmerican |
2.47410003595405E-09 |
| Normal-vs-Asian |
2.17209583652789E-11 |
| Caucasian-vs-AfricanAmerican |
1.537850E-01 |
| Caucasian-vs-Asian |
2.443000E-01 |
| AfricanAmerican-vs-Asian |
6.204800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.1836998048409E-10 |
| Normal-vs-Female |
1.62492241884138E-12 |
| Male-vs-Female |
1.963190E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63091762317435E-12 |
| Normal-vs-Age(41-60Yrs) |
8.88178419700125E-15 |
| Normal-vs-Age(61-80Yrs) |
6.07619510262225E-11 |
| Normal-vs-Age(81-100Yrs) |
6.538000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.474800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.199400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.480400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.191400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.860200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.524400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.160200E-01 |
| Classical-VS-Follicular |
3.682400E-01 |
| Classical-VS-Other |
4.940200E-01 |
| Classical-VS-Normal |
1.63247193540883E-12 |
| Tall-VS-Follicular |
9.559000E-01 |
| Tall-VS-Other |
3.443800E-01 |
| Tall-VS-Normal |
2.76059997084133E-09 |
| Follicular-VS-Other |
4.228600E-01 |
| Follicular-VS-Normal |
1.97689642433829E-11 |
| Other-VS-Normal |
1.354340E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.80331313717852E-13 |
| Normal-vs-N1 |
1.11022302462516E-16 |
| N0-vs-N1 |
7.337500E-03 |
|
|
